Mettler Toledo (MTD) Margin Slippage Tests Bullish Earnings Growth Narratives

Mettler-Toledo International Inc.

Mettler-Toledo International Inc.

MTD

0.00

Mettler-Toledo International (MTD) closed out FY 2025 with fourth quarter revenue of US$1,129.7 million and basic EPS of US$14.02, setting the tone for a year where trailing twelve month revenue reached US$4.0 billion and EPS came in at US$42.17. Over recent quarters the company has seen revenue move from US$954.5 million in Q3 2024 to US$1,129.7 million in Q4 2025, while quarterly EPS stepped from US$10.01 to US$14.02. This has left investors focused on how these trends flow through to slightly softer net margins and what that means for earnings quality.

See our full analysis for Mettler-Toledo International.

With the headline numbers on the table, the next step is to compare these results with the widely followed narratives around Mettler-Toledo International's growth, risks, and profitability to see which stories still hold up and which need a rethink.

NYSE:MTD Revenue & Expenses Breakdown as at May 2026
NYSE:MTD Revenue & Expenses Breakdown as at May 2026

TTM earnings and margins stay tightly grouped

  • Trailing twelve month net income is US$869.2 million on US$4.0b of revenue, which lines up with a 21.6% net margin compared with 22.3% a year earlier, and sits next to five year average earnings growth of 3.9% per year versus 0.7% over the last year.
  • Analysts' consensus view talks about sustained growth helped by automation and services, and this margin picture both supports and tests that idea:
    • On the supportive side, a 21.6% net margin on more than US$4.0b of trailing revenue and TTM EPS of US$42.17 shows the business is still generating high earnings per dollar of sales that align with the comment about higher margin recurring software and services.
    • On the testing side, the step down from 22.3% to 21.6% and trailing earnings growth of 0.7% versus the 3.9% five year pace leaves less evidence so far of the margin expansion that the consensus narrative connects to new pharma, biopharma, and food production investment.

Valuation caught between P/E and DCF fair value

  • The stock trades at US$1,319.29 with a trailing P/E of 30.7x, below both the peer average of 41.5x and the Global Life Sciences average of 37.1x, yet above the DCF fair value of US$1,219.11 and below the consensus analyst price target of US$1,488.31.
  • Consensus narrative language around long term demand and margin expansion meets mixed signals here:
    • Supportive for a constructive view, the lower P/E than peers and the industry can line up with the idea that recurring services and automation revenue provide durability, which some investors may see as not fully reflected in relative multiples.
    • More cautious for that same view, the current price sitting above DCF fair value of US$1,219.11 and below the US$1,488.31 target highlights that the market is already paying a premium to one cash flow model while still leaving a gap to what analysts expect on earnings and margin assumptions.

Growth forecasts versus recent 0.7% earnings lift

  • Earnings are reported as growing 0.7% over the last 12 months compared with a 3.9% per year five year average, while forecasts call for earnings growth of about 6.46% per year and revenue growth of about 4.7% per year.
  • Critics highlight in the bearish narrative that softer demand in China and Europe and slower replacement cycles could keep a lid on growth and margins, and the current numbers give that view some support:
    • Against the bearish concern, TTM revenue of about US$4.0b and net income of US$869.2 million show the business still producing sizeable profits, which is consistent with the description of high quality past earnings despite softer growth.
    • Backing the cautious angle, the 0.7% trailing earnings growth and 21.6% margin slightly below 22.3% a year ago leave a clear gap between what has actually happened over the last year and the 6.46% earnings and 4.7% revenue growth that forecasts are assuming.
On these numbers, it is worth seeing how bullish and bearish investors are framing the same data in their detailed narratives 📊 Read the what the Community is saying about Mettler-Toledo International..

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Mettler-Toledo International on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed views on growth, margins, and valuation, the real question is how you weigh the upside against the risks. Take a closer look at the underlying data, ask where you agree or disagree with the consensus, and then pressure test your stance against the 3 key rewards and 1 important warning sign 3 key rewards and 1 important warning sign

See What Else Is Out There

With earnings growth of 0.7% versus a 3.9% five year pace and softer margins, Mettler-Toledo International is not fully matching its growth narrative.

If those tempered trends leave you questioning the upside here, quickly compare this setup with companies that screens highlight as 51 high quality undervalued stocks and see if the risk reward trade off looks sharper.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.